
    
      The total study duration for a participant was 16-22 weeks (Part A) and 56-62 weeks (Part B)
      broken down as follows:

        -  Screening: Up to 4 weeks

        -  Treatment: 12 weeks (Part A) and 52 weeks (Part B)*

        -  Follow-up: 6 weeks (for participants who would not continue in the long-term extension
           study).

      '*' Participants successfully completing their treatment period would be offered the
      opportunity to enter the long term extension study LTS11210 (SARIL-RA-EXTEND) (NCT01146652).
    
  